Importance of Bilateral III for Switzerland as a pharma location

The Bilateral III, a third package of bilateral agreements between the European Union (EU) and Switzerland on participation in the Single Market, ensures unhindered access to the European internal market and puts the economic and political relationship with the EU on a solid foundation, says the Swiss trade group InterPharma.

Almost half of pharmaceutical exports go to the EU, which is why companies in Switzerland rely heavily on the updating of the technical barriers to trade - the agreement on the mutual recognition of conformity assessments  (MRA) - and the unhindered access to the EU internal market.

In addition, the free movement of people and cooperation in the field of research, in particular the association with Horizon Europe, are of central importance for the innovation location.